Evidence map›Paper›PMID 34408877›Full record

ReviewSAGE open medicine2021

New approaches and procedures for cancer treatment: Current perspectives.

Dejene Tolossa Debela, Seke Gy Muzazu, Kidist Digamo Heraro, Maureen Tayamika Ndalama, Betelhiem Woldemedhin Mesele, Dagimawi Chilot Haile, Sophia Khalayi Kitui, Tsegahun Manyazewal

Expression of concern Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in SAGE open medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. It is linked to trial NCT06929910 (Evaluation of Systemic Therapy and the Effectiveness of Circulating Tumor DNA), which is not on this map. Cited by 626 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
626citing papers in PubMed, 4 pooled it
73.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06929910 recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluation of Systemic Therapy and the Effectiveness of Circulating Tumor DNA (ctDNA) Assays in Monitoring Treatment Response in Patients With Metastatic Cancer Undergoing K4Care Testing

Typeobservational_patient_registrySponsorGene SolutionsRan2025 to 2027Enrolled200ConditionsMetastatic Cancers
3 · Its place in the literature

Who cites it

626 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,422 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. NbRSC advances · 2026
    Article
  8. Superantigens in Cancer Immunotherapy: Mechanisms, Engineering Strategies, and Therapeutic Potential.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. "What really works for us?" exploring therapeutic strategies for non-small cell lung cancer: an umbrella review of systematic reviews and meta-analyses.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

566 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Dejene Tolossa DebelaCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.ORCID 0000-0002-4615-5839
Seke Gy MuzazuCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Kidist Digamo HeraroCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Maureen Tayamika NdalamaCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Betelhiem Woldemedhin MeseleCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Dagimawi Chilot HaileCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Sophia Khalayi KituiCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Tsegahun ManyazewalCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.ORCID 0000-0002-8360-7574
Addis Ababa University · ETCentre for Infectious Disease Research in Zambia · ZMKotebe University of Education · ETWachemo University

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a global health problem responsible for one in six deaths worldwide. Treating cancer has been a highly complex process. Conventional treatment approaches, such as surgery, chemotherapy, and radiotherapy, have been in use, while significant advances are being made in recent times, including stem cell therapy, targeted therapy, ablation therapy, nanoparticles, natural antioxidants, radionics, chemodynamic therapy, sonodynamic therapy, and ferroptosis-based therapy. Current methods in oncology focus on the development of safe and efficient cancer nanomedicines. Stem cell therapy has brought promising efficacy in regenerating and repairing diseased or damaged tissues by targeting both primary and metastatic cancer foci, and nanoparticles brought new diagnostic and therapeutic options. Targeted therapy possessed breakthrough potential inhibiting the growth and spread of specific cancer cells, causing less damage to healthy cells. Ablation therapy has emerged as a minimally invasive procedure that burns or freezes cancers without the need for open surgery. Natural antioxidants demonstrated potential tracking down free radicals and neutralizing their harmful effects thereby treating or preventing cancer. Several new technologies are currently under research in clinical trials, and some of them have already been approved. This review presented an update on recent advances and breakthroughs in cancer therapies.

Indexed as

ablationCancergene therapynatural antioxidantsstem celltargeted drugstreatment

Identifiers

PMID34408877
PMCPMC8366192
OpenAlexW3190191592

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.